After years of an increasingly close relationship between the FDA and the pharmaceutical industry, an insider is finally speaking out. Dr. Raeford Brown, a pediatric anesthesiologist at the University of Kentucky Children’s Hospital and chair of the Food and Drug Administration (FDA) Committee on Analgesics and Anesthetics, has been openly critical of big pharma and the lack of proper oversight from the FDA, according to a new article on Yahoo Finance.Continue reading
The nation’s largest patient advocacy groups are on the front lines of some of the biggest health care debates, from the soaring costs of prescription drugs to whether new medicines are being approved quickly enough.
But while their voices carry weight because they represent the interests of sick patients, a new study has found that more than 80 percent of them accept funding from drug and medical-device companies. For some groups, the donations from industry accounted for more than half of their annual income, and in nearly 40 percent of cases, industry executives sit on governing boards, according to the study, which is published in The New England Journal of Medicine.
Nearly “nine out of every 10 are taking money,” said Dr. Ezekiel J. Emanuel, an oncologist and vice provost at the University of Pennsylvania. He is one of the authors of the study, which looked at the top 104 nonprofit patient advocacy groups that reported more than $7.5 million in annual revenues for 2014. “I think that is not well known — I think that is a shock.”
Dr. Emanuel, who previously advised President Obama on health care, said patient groups were far less transparent about conflicts of interest than medical researchers, who are now pushed to disclose ties to the drug and device industries when they write articles and make public appearances.